There is a number that sits at the heart of most NHS commissioning decisions for incretin-based obesity treatment, and it comes from an assumption that patients will escalate through a standard, monthly up-titration schedule to the maximum maintenance dose. As dosage increases, so does the cost. From that assumption flows a predicted cost per patient, which in turn shapes how services are planned, funded and evaluated. It is a reasonable place to start. The difficulty is that it may bear limited resemblance to what careful, personalised clinical management actually costs in practice.

Quantifying that gap has been difficult without real-world NHS data to work from, which is what makes the analysis we presented at the 33rd European Congress on Obesity worth examining in some detail. Across 90 consecutive patients completing 24 weeks of treatment through our partnership with East Suffolk and North Essex NHS Foundation Trust’s (ESNEFT) Complex Obesity Service, actual drug spend came in 17.9% below what a standard titration model would have predicted, representing a mean saving of £174.71 per patient over six months based on BNF prices at the time. That pattern held across semaglutide, tirzepatide and patients who switched between therapies at some point during treatment.

Modelled nationally, against an eligible population of 2.4 million patients, the equivalent saving would be in the region of £420 million over six months alone. That is not a marginal efficiency. It is the kind of figure that could meaningfully extend the reach of NHS obesity treatment. Put another way, that 17.9% reduction generates a 22% uplift in available medication funding during a patient's first six months. By optimising the initiation phase, we fundamentally change the economics of the pathway, creating immediate financial capacity to support service expansion.

This is about optimisation, not therapeutic inertia. Of 610 dosing decisions analysed across the cohort, 31% resulted in a dose lower than the standard schedule, primarily through personalised dose holds made on clinical grounds. These were deliberate decisions made in partnership with patients, to take into account individualised responses to the medication, not unintended protocol deviations or gaps in care.

Reset Health’s platform underpins this model, enabling the kind of continuous, clinician-led oversight that makes genuinely personalised dosing decisions possible within an NHS service. The same cohort achieved 95.7% retention on treatment and a mean weight loss of 10.3% at six months. The savings and the outcomes came from the same place.

For commissioning, there are practical consequences to this. If the financial models underpinning NHS obesity service decisions are built on standard titration assumptions, they will tend to overestimate the cost of well-managed, clinician-led care, and in doing so will systematically undervalue the contribution that active clinical oversight makes to overall efficiency. A service that invests in the infrastructure to manage dosing decisions carefully is not a more expensive option. It may, in fact, be a more cost efficient one.

As incretin therapies are commissioned more widely across the NHS, the quality of the financial models informing those decisions will matter enormously. Getting them right means building them on data that reflects how good clinical care actually works.